Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
Michael Singer,1 Mimi Liu,2 Patricio G Schlottmann,3 Arshad M Khanani,4 Miranda Hemphill,5 Lauren Hill,5 Lisa Tuomi,5 Zdenka Haskova5 1Medical Center Ophthalmology Associates, San Antonio, TX, USA; 2Colorado Retina Associates, Denver, CO, USA; 3Organizacion Medica de Investigacion, Buenos Aires, Arg...
Guardado en:
Autores principales: | Singer M, Liu M, Schlottmann PG, Khanani AM, Hemphill M, Hill L, Tuomi L, Haskova Z |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bb4def1039f742bd8d26c58fd00fc64b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013) -
Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016) -
Prospective, Single-Center, Six-Month Study of Intravitreal Ranibizumab for Macular Edema with Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-Perfused Retinal Area
por: Lee SJ, et al.
Publicado: (2020) -
Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population
por: Pramanik S, et al.
Publicado: (2021) -
Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema
por: Varma R, et al.
Publicado: (2020)